Kardiovaskuläre Magnetresonanztomografie – Pro und Contra

Zusammenfassung

Die kardiovaskuläre MRT hat in den vergangenen Jahren eine erhebliche Weiterentwicklung zu einem in der Kardiologie unverzichtbaren bildgebenden Verfahren vollzogen. Sie ermöglicht auf einzigartige Weise eine flexible und gleichzeitig umfassende Integration verschiedener Techniken mit hoher Genauigkeit zur Beurteilung von kardialer Morphologie, Funktion und Gewebecharakterisierung. Unter Berücksichtigung einiger wichtiger Limitationen ist die MRT mittlerweile bei vielen Herzerkrankungen in Bezug auf Diagnose und Prognose die bildgebende Methode der Wahl geworden.

Abstract

In recent years cardiovascular MRI (CMR) has demonstrated tremendous advancements towards an indispensable imaging tool in cardiovascular medicine. CMR uniquely allows a flexible and comprehensive integration of different techniques with high accuracy for the evaluation of cardiac morphology, function and tissue characterization. Considering a few important limitations, CMR has become the imaging method of choice for the diagnostic and prognostic workup of many cardiac diseases.

Schlüsselwörter

kardiale Magnetresonanztomografie - myokardiale Ischämie - Kardiomyopathie - Myokarditis

Key words

cardiac magnetic resonance - myocardial ischemia - cardiomyopathy - myocarditis

• Literatur

• 1 von Knobelsdorff-Brenkenhoff F, Schulz-Menger J. Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology. J Cardiovasc Magn Reson 2016; 18: 6
• 2 Puntmann VO, Peker E, Chandrashekhar Y et al. T1 Mapping in Characterizing Myocardial Disease: A Comprehensive Review. Circ Res 2016; 119: 277-299
• 3 Authors/Task Force members Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-2619
• 4 Gebker R, Jahnke C, Manka R et al. The role of dobutamine stress cardiovascular magnetic resonance in the clinical management of patients with suspected and known coronary artery disease. J Cardiovasc Magn Reson 2011; 13: 46
• 5 Greenwood JP, Maredia N, Younger JF et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet 2012; 379: 453-460
• 6 Danad I, Szymonifka J, Twisk JW et al. Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a meta-analysis. Eur Heart J 2016; DOI: 10.1093/eurheartj/ehw095.
• 7 Lipinski MJ, McVey CM, Berger JS et al. Prognostic value of stress cardiac magnetic resonance imaging in patients with known or suspected coronary artery disease: a systematic review and meta-analysis. J Am Coll Cardiol 2013; 62: 826-838
• 8 Kelle S, Chiribiri A, Vierecke J et al. Long-term prognostic value of dobutamine stress CMR. JACC Cardiovasc Imaging 2011; 4: 161-172
• 9 Jahnke C, Nagel E, Gebker R et al. Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation 2007; 115: 1769-1776
• 10 Romero J, Xue X, Gonzalez W et al. CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease: a meta-analysis of prospective trials. JACC Cardiovasc Imaging 2012; 5: 494-508
• 11 Eitel I, Kubusch K, Strohm O et al. Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation-myocardial infarction. Circ Cardiovasc Imaging 2011; 4: 354-362
• 12 Authors/Task Force members Elliott PM, Anastasakis A, Borger MA. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733-2779
• 13 Chan RH, Maron BJ, Olivotto I et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014; 130: 484-495
• 14 Gulati A, Jabbour A, Ismail TF et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 2013; 309: 896-908
• 15 Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200
• 16 Marcus FI, McKenna WJ, Sherrill D et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010; 121: 1533-1541
• 17 Petersen SE, Selvanayagam JB, Wiesmann F et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol 2005; 46: 101-105
• 18 Friedrich MG, Sechtem U, Schulz-Menger J et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol 2009; 53: 1475-1487
• 19 Grün S, Schumm J, Greulich S et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 2012; 59: 1604-1615
• 20 Hombach V, Kelle S, Gebker R et al. Curriculum Kardiale Magnetresonanztomographie (CMR). Kardiologe 2014; 8: 451-461